Non-Bacterial Infection of Nervous System w/ MCC DRG Reimbursement

DRG 097 encompasses non-bacterial infections of the nervous system except viral meningitis when a Major Complication or Comorbidity is present; it addresses high-acuity neuroinfectious conditions requiring intensive inpatient resources. Proper classification influences Medicare inpatient reimbursement because the Major Complication or Comorbidity status increases the payment weight to account for greater clinical complexity and resource consumption.

DRG 097 Overview

DRG 097 covers non-bacterial infections of the nervous system excluding viral meningitis when a Major Complication or Comorbidity is present, such as severe encephalitis, myelitis, or other acute neuroinflammatory conditions with significant organ dysfunction. This Diagnosis-Related Group captures high-acuity infectious neurologic admissions that drive longer lengths of stay and higher resource use. It matters for Medicare payment because the presence of a Major Complication or Comorbidity elevates reimbursement to reflect increased intensity of care and ancillary services. Accurate clinical coding and documentation determine assignment to this Diagnosis-Related Group and associated inpatient payment.

Trials evaluating rapid diagnostic and immunomodulatory strategies for acute non-bacterial central nervous system infections with major complications: studies in this category focus on early diagnostic algorithms (advanced CSF biomarker panels, multiplex PCR, and neuroimaging protocols) combined with timing and dosing of broad immunomodulatory interventions (for example, corticosteroids or other anti-inflammatory regimens) during the initial hospitalization. The patient population includes adults and older adults admitted with encephalitis, spinal infections, or other non-bacterial CNS infections who develop major complications such as seizures, altered consciousness, or respiratory failure. This research is relevant to providers and payers because faster, accurate diagnosis and optimized acute treatment can reduce ICU utilization, shorten LOS, and lower costs associated with complications and prolonged supportive care.
Comparative effectiveness studies of infectious vs immune-mediated etiologies and care pathways in severe non-bacterial CNS infection: these observational and pragmatic randomized studies compare outcomes across diagnostic-based care pathways (for example, empiric antiviral and supportive care versus protocols that escalate to targeted immunotherapies when autoimmune or parainfectious causes are suspected). They enroll heterogeneous inpatients with non-bacterial CNS infections who have major complications, stratifying by age, comorbidity, and severity, to determine which diagnostic-to-treatment sequences yield better neurologic recovery and lower resource use. Findings inform clinicians and payers about which care pathways provide the best balance of clinical benefit and cost-effectiveness for high-acuity patients coded to this DRG.
Post-discharge rehabilitation, readmission prevention, and long-term outcome studies for survivors with major neurologic sequelae: prospective cohort and interventional trials in this area test structured inpatient-to-outpatient transition programs, early multidisciplinary rehabilitation regimens, and remote-monitoring strategies aimed at reducing 30- and 90-day readmissions and improving functional recovery in patients who required ICU-level care during hospitalization. The target population is survivors of non-bacterial CNS infections with major complications (cognitive impairment, motor deficits, or seizure disorders) who are at high risk for rehospitalization and durable disability. These studies are important to payers and providers because improved transitions and rehabilitation can lower downstream costs, reduce readmissions tied to complications or medication issues, and improve long-term quality metrics tied to this DRG.

Trials evaluating rapid diagnostic and immunomodulatory strategies for acute non-bacterial central nervous system infections with major complications: studies in this category focus on early diagnostic algorithms (advanced CSF biomarker panels, multiplex PCR, and neuroimaging protocols) combined with timing and dosing of broad immunomodulatory interventions (for example, corticosteroids or other anti-inflammatory regimens) during the initial hospitalization. The patient population includes adults and older adults admitted with encephalitis, spinal infections, or other non-bacterial CNS infections who develop major complications such as seizures, altered consciousness, or respiratory failure. This research is relevant to providers and payers because faster, accurate diagnosis and optimized acute treatment can reduce ICU utilization, shorten LOS, and lower costs associated with complications and prolonged supportive care.
Comparative effectiveness studies of infectious vs immune-mediated etiologies and care pathways in severe non-bacterial CNS infection: these observational and pragmatic randomized studies compare outcomes across diagnostic-based care pathways (for example, empiric antiviral and supportive care versus protocols that escalate to targeted immunotherapies when autoimmune or parainfectious causes are suspected). They enroll heterogeneous inpatients with non-bacterial CNS infections who have major complications, stratifying by age, comorbidity, and severity, to determine which diagnostic-to-treatment sequences yield better neurologic recovery and lower resource use. Findings inform clinicians and payers about which care pathways provide the best balance of clinical benefit and cost-effectiveness for high-acuity patients coded to this DRG.
Post-discharge rehabilitation, readmission prevention, and long-term outcome studies for survivors with major neurologic sequelae: prospective cohort and interventional trials in this area test structured inpatient-to-outpatient transition programs, early multidisciplinary rehabilitation regimens, and remote-monitoring strategies aimed at reducing 30- and 90-day readmissions and improving functional recovery in patients who required ICU-level care during hospitalization. The target population is survivors of non-bacterial CNS infections with major complications (cognitive impairment, motor deficits, or seizure disorders) who are at high risk for rehospitalization and durable disability. These studies are important to payers and providers because improved transitions and rehabilitation can lower downstream costs, reduce readmissions tied to complications or medication issues, and improve long-term quality metrics tied to this DRG.

OpenPayer

Summary & Overview

Non-Bacterial Infection of Nervous System Except Viral Meningitis with MCC: Inpatient Reimbursement Overview

DRG 097 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes